Morgan Stanley’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $34.2K | Sell |
91,338
-8,831
| -9% | -$4.66K | ﹤0.01% | 6631 |
|
|
2026
Q1 | $56.7K | Sell |
100,169
-16,311
| -14% | -$11.1K | ﹤0.01% | 6379 |
|
|
2025
Q4 | $74.5K | Buy |
116,480
+9,224
| +9% | +$7.1K | ﹤0.01% | 6304 |
|
|
2025
Q3 | $100K | Buy |
107,256
+1,846
| +2% | +$1.82K | ﹤0.01% | 6152 |
|
|
2025
Q2 | $135K | Sell |
105,410
-297
| -0.3% | -$298 | ﹤0.01% | 6020 |
|
|
2025
Q1 | $106K | Sell |
105,707
-918
| -0.9% | -$967 | ﹤0.01% | 5987 |
|
|
2024
Q4 | $97K | Sell |
106,625
-7,354
| -6% | -$7.22K | ﹤0.01% | 6072 |
|
|
2024
Q3 | $171K | Sell |
113,979
-244
| -0.2% | -$268 | ﹤0.01% | 5809 |
|
|
2024
Q2 | $80.3K | Sell |
114,223
-2,162
| -2% | -$1.88K | ﹤0.01% | 6040 |
|
|
2024
Q1 | $111K | Sell |
116,385
-123,571
| -51% | -$120K | ﹤0.01% | 5950 |
|
|
2023
Q4 | $266K | Buy |
239,956
+116,648
| +95% | +$173K | ﹤0.01% | 5836 |
|
|
2023
Q3 | $232K | Sell |
123,308
-191
| -0.2% | -$548 | ﹤0.01% | 5517 |
|
|
2023
Q2 | $443K | Sell |
123,499
-2,478
| -2% | -$7.83K | ﹤0.01% | 5280 |
|
|
2023
Q1 | $425K | Buy |
125,977
+14,634
| +13% | +$43.9K | ﹤0.01% | 5349 |
|
|
2022
Q4 | $173K | Buy |
111,343
+7,791
| +8% | +$11.6K | ﹤0.01% | 5728 |
|
|
2022
Q3 | $140K | Sell |
103,552
-205,560
| -67% | -$401K | ﹤0.01% | 5903 |
|
|
2022
Q2 | $677K | Buy |
309,112
+117,763
| +62% | +$270K | ﹤0.01% | 5259 |
|
|
2022
Q1 | $610K | Buy |
191,349
+13,202
| +7% | +$47.3K | ﹤0.01% | 5289 |
|
|
2021
Q4 | $745K | Sell |
178,147
-68,215
| -28% | -$383K | ﹤0.01% | 5286 |
|
|
2021
Q3 | $2M | Buy |
246,362
+10,239
| +4% | +$83.2K | ﹤0.01% | 4585 |
|
|
2021
Q2 | $1.78M | Buy |
236,123
+35,166
| +17% | +$296K | ﹤0.01% | 4721 |
|
|
2021
Q1 | $1.74M | Sell |
200,957
-5,614
| -3% | -$53.5K | ﹤0.01% | 4359 |
|
|
2020
Q4 | $1.65M | Buy |
206,571
+27,948
| +16% | +$234K | ﹤0.01% | 4315 |
|
|
2020
Q3 | $1.42M | Buy |
178,623
+7,465
| +4% | +$67.4K | ﹤0.01% | 3949 |
|
|
2020
Q2 | $1.7M | Sell |
171,158
-91,978
| -35% | -$845K | ﹤0.01% | 3749 |
|
|
2020
Q1 | $2.03M | Sell |
263,136
-117,746
| -31% | -$594K | ﹤0.01% | 3354 |
|
|
2019
Q4 | $1.47M | Buy |
380,882
+298,247
| +361% | +$1.3M | ﹤0.01% | 4266 |
|
|
2019
Q3 | $415K | Buy |
82,635
+44,580
| +117% | +$259K | ﹤0.01% | 4772 |
|
|
2019
Q2 | $252K | Sell |
38,055
-3,458
| -8% | -$23.8K | ﹤0.01% | 4926 |
|
|
2019
Q1 | $314K | Sell |
41,513
-31,176
| -43% | -$243K | ﹤0.01% | 4819 |
|
|
2018
Q4 | $587K | Sell |
72,689
-5,511
| -7% | -$54.7K | ﹤0.01% | 4685 |
|
|
2018
Q3 | $1.01M | Sell |
78,200
-7,672
| -9% | -$96.2K | ﹤0.01% | 4531 |
|
|
2018
Q2 | $979K | Buy |
85,872
+62,679
| +270% | +$593K | ﹤0.01% | 4646 |
|
|
2018
Q1 | $163K | Buy |
23,193
+15,137
| +188% | +$114K | ﹤0.01% | 5548 |
|
|
2017
Q4 | $52K | Buy |
8,056
+1,194
| +17% | +$7.59K | ﹤0.01% | 5829 |
|
|
2017
Q3 | $43K | Buy |
6,862
+4,355
| +174% | +$22.2K | ﹤0.01% | 5829 |
|
|
2017
Q2 | $11K | Sell |
2,507
-2,734
| -52% | -$12K | ﹤0.01% | 6212 |
|
|
2017
Q1 | $23K | Buy |
5,241
+4,088
| +355% | +$22.8K | ﹤0.01% | 6043 |
|
|
2016
Q4 | $6K | Sell |
1,153
-977
| -46% | -$5.35K | ﹤0.01% | 6250 |
|
|
2016
Q3 | $14K | Hold |
2,130
| – | – | ﹤0.01% | 6025 |
|
|
2016
Q2 | $10K | Sell |
2,130
-1,224
| -36% | -$5.33K | ﹤0.01% | 6058 |
|
|
2016
Q1 | $13K | Buy |
3,354
+956
| +40% | +$4.15K | ﹤0.01% | 6048 |
|
|
2015
Q4 | $13K | Sell |
2,398
-69
| -3% | -$470 | ﹤0.01% | 6174 |
|
|
2015
Q3 | $16K | Sell |
2,467
-114,103
| -98% | -$761K | ﹤0.01% | 6114 |
|
|
2015
Q2 | $715K | Buy |
116,570
+68,633
| +143% | +$467K | ﹤0.01% | 4448 |
|
|
2015
Q1 | $632K | Buy |
+47,937
| New | +$493K | ﹤0.01% | 4487 |
|
Other funds holding CTSO
AC
VCM
CM
SC
SIG
VFT
Morgan Stanley's CTSO Position: Q2 2026 in Review
Morgan Stanley reduced its Cytosorbents Corp (CTSO) stake by 8.8% in Q2 2026, selling an estimated $4.66K and leaving 91,338 shares worth $34.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6631.
Morgan Stanley first reported a position in CTSO in Q1 2015 and has held it in 46 quarters since. The position peaked at $2.03M in Q1 2020. 42 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Morgan Stanley held 91,338 shares of Cytosorbents Corp worth $34.2K as of Q2 2026.
- Morgan Stanley sold 8,831 Cytosorbents Corp shares in Q2 2026, an estimated $4.66K.
- Cytosorbents Corp made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6631 holding.
- Morgan Stanley first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 46 quarters since.
- Morgan Stanley's Cytosorbents Corp position peaked at $2.03M in Q1 2020.
- 42 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.